Stryker (NYSE:SYK – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 14.950-15.100 for the period, compared to the consensus EPS estimate of 14.980. The company issued revenue guidance of -.
Stryker Price Performance
SYK stock traded down $3.88 during mid-day trading on Thursday, hitting $348.37. 2,766,545 shares of the stock were exchanged, compared to its average volume of 2,241,684. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business has a fifty day moving average price of $317.08 and a 200 day moving average price of $334.98. Stryker has a 12 month low of $281.00 and a 12 month high of $401.99. The stock has a market capitalization of $133.55 billion, a price-to-earnings ratio of 40.32, a PEG ratio of 2.26 and a beta of 0.77.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts anticipate that Stryker will post 14.99 EPS for the current year.
Stryker Dividend Announcement
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. UBS Group initiated coverage on shares of Stryker in a research note on Tuesday. They issued a “buy” rating and a $400.00 price objective for the company. Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Canaccord Genuity Group decreased their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $393.39.
Check Out Our Latest Analysis on Stryker
Insider Buying and Selling at Stryker
In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by insiders.
Stryker News Summary
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: Stryker reported second-quarter adjusted earnings of $3.69 per share, ahead of estimates ranging from $3.46 to $3.49 and up from $3.13 a year earlier. Revenue reached $6.59 billion, narrowly exceeding expectations and increasing 9.4% year over year. Stryker Q2 Earnings and Revenues Beat Estimates
- Positive Sentiment: Strong demand for implants and devices used in complex spinal and orthopedic procedures supported the quarterly results, indicating resilient underlying demand for Stryker’s medical technology products. Stryker Beats Quarterly Estimates on Strong Demand
- Positive Sentiment: Management provided full-year 2026 EPS guidance of $14.95 to $15.10, broadly above the current analyst consensus of approximately $14.98, supporting expectations for continued earnings growth.
- Positive Sentiment: UBS initiated coverage with a Buy rating and a $400 price target, implying meaningful upside from recent trading levels and adding a new bullish analyst view. UBS Initiates Stryker Coverage
- Neutral Sentiment: Stryker reported approximately $1.28 billion in profit and said it is making progress recovering from a March cyberattack. However, the recovery remains an operational consideration for investors. Stryker Logs Higher Profit Amid Cyberattack Recovery
- Negative Sentiment: Medical-product companies continue to face potential margin pressure from tariffs and inflation. That concern may temper the market’s reaction to Stryker’s earnings beat, particularly given the stock’s elevated valuation.
Hedge Funds Weigh In On Stryker
A number of hedge funds have recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new position in shares of Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP raised its holdings in shares of Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker in the second quarter worth $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More
- Five stocks we like better than Stryker
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
